<DOC>
	<DOCNO>NCT00769080</DOCNO>
	<brief_summary>The purpose study compare 1-year adherence upfront adjuvant AI postmenopausal , early stage breast cancer two observational arm ; Standard Treatment Standard Treatment plus PSP arm one year</brief_summary>
	<brief_title>The Performance Patient Support Program Early Stage Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Provide sign date write Informed Consent Have take upfront AI adjuvant therapy line current SmPC Be capable complete drug intake Be capable understand Chinese Upfront adjuvant hormonal therapy AI upfront adjuvant indication grant SFDA Upfront adjuvant AI medication exceed eight week Previous adjuvant hormonal therapy breast cancer last 8 week AI Involvement plan conduct study ( applies AstraZeneca staff staff study site )</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>PSP</keyword>
	<keyword>Standard Treatment</keyword>
	<keyword>Standard Treatment plus PSP</keyword>
</DOC>